Received May 19, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | — | — |
The Second Dose of Heplisav-B Was Given Too Soon; Initial report received on 07-May-2026. A nurse reported that a male patient (race and ethnicity not reported) received the second dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization too soon. No medical history or concomitant medications were reported. On 13-Apr-2026, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number, expiration date, NDC #, route, and site not reported). On 27-Apr-2026, 15 days after receiving dose one of HEPLISAV-B, the patient received dose 2 of HEPLISAV-B (lot number, expiration date, NDC #, route, and site not reported). No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.
Medical History/Concurrent Conditions: No adverse event